Company Overview and News

 
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

 
D-Street Buzz: Realty stocks plunge with Indiabulls Real Estate down 13%; Biocon hits new 52-week high

2018-09-25 moneycontrol
The Indian stock market continues to trade on a positive note this Tuesday afternoon with the Nifty50 is up 14 points and is trading at 10,981 while the Sensex is trading higher by 135 points at 36,440.
IOC ESL 500325 AUROPHARMA RELIANCE 532617 HINDUNILVR 532832 531795 535789 505200 ALLCARGO ENGINERSIN RIGD 500696 GAILF EICHERMOT 503100 RLNIY YESBANK ECQRY PHOENIXLTD 524804 511072 IDKQY 532749 ATULAUTO JETAIRWAYS CANFINHOME 533264 532648 YYBKY 511196 530965 IBULHSGFIN 532178 DHFL ARBQY GAILY IBREALEST

1
D-Street Buzz: Pharma stocks gain led by Dr Reddy#39;s Labs; HCL Tech hits new 52-week high, DHFL tanks 20%

2018-09-25 moneycontrol
The Indian stock market has witnessed some handsome bounce back as the benchmark indices have regained some lost grounds this Tuesday afternoon. The Nifty50 is up 43 points and is trading at 11,o1o while the Sensex is trading higher by 176 points at 36,481.
ESL INDIANB 533452 532832 531795 535789 EICHERMOT GRUH AXB 524804 511072 JETAIRWAYS CANFINHOME YYBKY 511196 AXBA DHFL TATASTEEL TATLY 500180 IBREALEST WEIZFOREX AUROPHARMA 532617 533273 532814 532215 511288 505200 500470 532187 AXISBANK ENGINERSIN HDFCBANK 500153 503100 YESBANK ECQRY PHOENIXLTD INDUSINDBK IDKQY ATULAUTO 533264 532648 GRHFY AXBKY IBULHSGFIN 532178 OBZIY TTST OBEROIRLTY GANESHBE HDB ARBQY

 
D-Street Buzz: IT, pharma stocks up on weak rupee led by Aurobindo Pharma, HCL Tech; RIL gains

2018-09-25 moneycontrol
There is no stopping the slide in the Indian stock market as the benchmark indices have yet again opened lower amid higher crude oil prices and a falling rupee. The Nifty50 is down 48 points and is trading below 11,ooo at 10,919 while the Sensex is trading lower by 119 points at 36,185.
523768 ESL RTI RLTAY 500325 82HP TCHQY 532636 IIFL 532832 532755 539437 531795 535789 532121 SONATSOFTW BJJQY GAILF EICHERMOT RLNIY GRUH AXB 524804 511072 JETAIRWAYS CANFINHOME YYBKY 511196 TECHM AXBA DHFL BAJFINANCE TATASTEEL TATLY GAILY KOTAKBANK VSTIND IBREALEST AUROPHARMA GUJBOROS 539254 RELIANCE 532617 532215 511288 505200 509966 532221 500470 532187 IDFCBANK AXISBANK ENGINERSIN RIGD 500034 ADANITRANS YESBANK ECQRY INDUSINDBK KMBKY IDKQY ATULAUTO 533264 532648 GRHFY AXBKY IBULHSGFIN 532178 TTST ARBQY 500366 500247 ROLTA DENABANK

 
Aurobindo Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

 
Aurobindo Pharma gets nod from South African health authority for HIV drug

2018-09-18 moneycontrol
Aurobindo Pharma Tuesday said it has received approval from the South African health authority to market its Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (DLT) tablets, the first-line regimen for HIV patients as per latest WHO guidelines.
AUROPHARMA 524804 ARBQY

 
Aurobindo Pharma shares gain over 1% on SAHPRA approval for HIV drug

2018-09-18 moneycontrol
Aurobindo Pharma share price gained more than a percent in morning on Tuesday on receiving approval from South African health regulator for latest fixed dose triple combination tablets.
AUROPHARMA 524804 ARBQY

 
Aurobindo Pharma Limited - Press Release

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

 
D-Street Buzz: IT stocks gain led by Oracle Financial; sugar stocks continue to rally, RIL drags

2018-09-17 moneycontrol
The Indian stock market have extended the morning loses and are trading well in the red this Monday afternoon with the Nifty50 down 102 points and is trading at 11,412 while the Sensex is trading lower by 391 points at 37,699.
GRASIM IOC 500408 SUZLON 500325 BRTQY TCHQY 532755 SONATSOFTW 532480 500696 BJJQY BRITANNIA SUEL RLNIY 504212 SBAZ GRSJY 524804 UNITDSPR ALBK YYBKY 530965 532667 TECHM 532432 BAJFINANCE TATASTEEL TATLY UQNTY 500300 500825 AUROPHARMA 533271 GODREJIND RELIANCE 512573 HINDUNILVR ASHOKA 532221 500470 RIGD SAKHTISUG UNIVCABLES 500034 YESBANK UBNC AVANTI 532648 GRSXY TTST ARBQY TATAELXSI 507315 500164

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...